Ensitrelvir - CAS# 2647530-73-0 hyl 3 4 5-trimethoxybenzoate Smiles: N[C@@H]1CC[C@H](CC1)NC1N=C(NC2C=CC(CN3CCOCC3)=CC=2)C2N=CN(C3CCCC3)C=2N=1

Smiles: N[C@@H]1CC[C@H](CC1)NC1N=C(NC2C=CC(CN3CCOCC3)=CC=2)C2N=CN(C3CCCC3)C=2N=1

50 and 100 µM

JP83 was found to be able to inhibit FAAH with equal or greater potency than URB597

Temporin A is a short alpha-helical antimicrobial peptide isolated from the skin of the frog Rana temporaria

CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo

Ensitrelvir - CAS# 2647530-73-0 hyl 3 4 5-trimethoxybenzoate Smiles: N[C@@H]1CC[C@H](CC1)NC1N=C(NC2C=CC(CN3CCOCC3)=CC=2)C2N=CN(C3CCCC3)C=2N=1Ensitrelvir, CAS No. 2647530 73 0 , also known as S 217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C like protease inhibitor for the treatment of COVID 19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non covalent, non peptidic, SARS CoV 2 3CL protease inhibitor (IC50=13 nM). It